Clinical trials: Development Disorders
Adult Growth Hormone Deficiency, Endocrine System Diseases
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly.
- Conditions
- Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Trial name
- NCT05171855
- Testing
- Lonapegsomatropin
- Where
- 85 sites in United States, Armenia and 19 more
- Volunteers
- 220 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Autism Spectrum Disorder, Developmental Disorder
Children's Autism Metabolome Project
Development and Clinical Evaluation of the Stemina Metabolic Biomarker-Based Test to Diagnose Autism Spectrum Disorder in Early Childhood.
- Trial name
- CAMP-01 (NCT02548442)
- Where
- 8 sites in United States
- Volunteers
- 1,102 people, healthy volunteers welcome
- Sponsor
- Stemina Biomarker Discovery, Inc.
Growth Hormone Deficiency With Pituitary Anomalies
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
The Macimorelin Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, 2-way crossover Trial.
- Trial name
- NCT02558829
- Testing
- Macimorelin, Insulin
- Where
- 27 sites in United States, Austria and 7 more
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- AEterna Zentaris
Hypochondroplasia
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).
- Trial name
- CANOPY-HCH-3 (NCT06455059)
- Testing
- Vosoritide
- Where
- 23 sites in United States, Australia and 7 more
- Volunteers
- 80 people
- Sponsor
- BioMarin Pharmaceutical
Dwarfism, Pituitary
National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients
This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech GH preparations to treat GH-deficient subjects with optimal GH dosing during puberty.
- Trial name
- NCT00097513
- Where
- United States
- Sponsor
- Genentech, Inc.
Influenza
Development of an Intranasal Proteosome Influenza Vaccine
A study to compare multiple dosage regimes of a protesomal intranasal vaccine.
- Trial name
- NCT02522754
- Testing
- Experimental: Protesomal Vaccine 1 x 30 µg, Experimental: Protesomal Vaccine 2 x 30 µg, Experimental: Protesomal Vaccine 2 x 15 µg
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Hvivo
Autism Spectrum Disorder (ASD), Autism
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
The objective of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of pediatric patients with autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified…
- Conditions
- Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder
- Trial name
- NCT01592773
- Testing
- Memantine Hydrochloride (HCl)
- Where
- 106 sites in United States, Belgium and 14 more
- Volunteers
- 747 people
- Sponsor
- Forest Laboratories
Covid19
Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg)
Coronavirus Disease 2019 (COVID-19) is a newly emerged disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04586413
- Testing
- No intervention - quality of life measure
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Medialis Ltd.
Adult Growth Hormone Deficiency
Versartis International Trial in Adults With Long-Acting Growth Hormone
A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for five months in adults with GHD.
- Trial name
- VITAL (NCT02526420)
- Testing
- somavaratan
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 36 people
- Sponsor
- Versartis Inc.
Dwarfism, Pituitary
Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children
This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad population of children.
- Trial name
- NCT02314676
- Testing
- PEG-somatropin
- Where
- 2 sites in China
- Volunteers
- 900 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Cataract and IOL Surgery
Development of Optical Biometer
The Helioscope (Cassini Technologies B.V.) is a novel device under development that aims at combining LED-based corneal topography and SS-OCT to provide accurate and fast measurements of both the corneal shape and the ocular…
- Trial name
- CH-0203 (NCT07325162)
- Testing
- New Investigational Optical Biometer (Device), Comparator Device A (Cassini Ambient), omparator Device B (Argos)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cassini Technologies
Spinal Cord Neoplasms, Spinal Fractures
The Development of a Vertebra Localizing Aid Medical Device
The current method of incision localization in many surgical procedures requires a doctor to reference a medical image, such as an X-ray, to judge where on the body an incision should be made.
- Trial name
- NCT02603874
- Testing
- Target Tape
- Volunteers
- 100 people
- Sponsor
- Target Tape
Dentin Sensitivity
A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity
To investigate the efficacy of an experimental oral rinse, containing 1.5% potassium oxalate (KOX) and 0 parts per million (ppm) fluoride in relieving dentine hypersensitivity (DH) after 8 weeks use compared with a placebo oral…
- Trial name
- NCT03238352
- Testing
- Potassium oxalate, Sodium fluoride
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acromegaly
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison…
- Trial name
- OXTEND™-03 (NCT06930625)
- Testing
- Debio 4126
- Where
- 74 sites in United States, Austria and 19 more
- Volunteers
- 119 people
- Sponsor
- Debiopharm International SA
Growth Disorders
Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
This is an extension study to Tercica study MS301 (NCT00125164) and is intended to collect long term safety and efficacy data on the continued use of recombinant human insulin-like growth factor-1 (rh IGF-1) in children and…
- Trial name
- NCT00330668
- Testing
- rh IGF-1 (mecasermin)
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Ipsen
Irritability Associated With Autism Spectrum Disorder, Autism Spectrum Disorder
A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder
Behavior dysregulation is commonly associated with people with autism spectrum disorder (ASD). Irritability is a major safety concern in adults with ASD.
- Conditions
- Irritability Associated With Autism Spectrum Disorder, Autism Spectrum Disorder, ASD
- Trial name
- NCT05733390
- Testing
- JZP541
- Where
- United States
- Sponsor
- Jazz Pharmaceuticals
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Autism
Acuity Functional Impact and Implementation Outcomes Evaluation
This study will test feature enhancements to a behavioral therapy data collection software (Motivity) that will add a new clinical decision support module, called Acuity.
- Trial name
- NCT06561581
- Testing
- Acuity
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Experiad LLC
Developmental and Epileptic Encephalopathy, Dravet Syndrome
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.
- Conditions
- Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox Gastaut Syndrome
- Trial name
- PACIFIC (NCT05364021)
- Testing
- LP352
- Where
- 34 sites in United States, Australia
- Volunteers
- 52 people
- Sponsor
- Longboard Pharmaceuticals
SLC6A1 Neurodevelopmental Disorder (NDD), Developmental and Epileptic Encephalopathies (DEE)
SLC6A1-NDD Prospective Longitudinal Natural History Study
The overall objective of this prospective longitudinal natural history study is to collect clinical data to characterize and evaluate the natural course of SLC6A1-NDD and assess the feasibility of certain assessments for the…
- Trial name
- SPIRIT (NCT07531511)
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- UCB Biopharma SRL
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.